Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Breast cancer tumor related tumor marker, application and kit

A tumor marker, breast cancer tumor technology, applied in the field of tumor molecular diagnosis, can solve problems such as side effects, lack of breast cancer stem cell markers, etc., achieving profound clinical significance and important promotion and application prospects.

Pending Publication Date: 2020-07-28
深圳市因诺转化医学研究院 +1
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are problems in the targeted therapy of markers and signaling pathways related to breast cancer stem cells: no specific markers of breast cancer stem cells with therapeutic value have been found; signal transduction pathways are also expressed in normal cells, Drugs that work by inhibiting pathways have also been reported to have severe side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Breast cancer tumor related tumor marker, application and kit
  • Breast cancer tumor related tumor marker, application and kit
  • Breast cancer tumor related tumor marker, application and kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Comparison of the relationship between the expression of the PHF20 gene and the survival rate in breast cancer patients

[0032] In order to understand the expression of PHF20 in the tumor tissue of breast cancer patients, and the correlation between the expression level and the survival period, we analyzed the expression level of PHF20mRNA in the tumor samples of 302 breast cancer patients in the TCTA database. The average value of PHF20 is the cut-off point, and the patients are divided into patients with high expression of PHF20 (42 cases) and patients with low expression of PHF20 (260 cases). Combined with the follow-up data of the patients, we found that the higher the expression of PHF20, the higher the patient’s The shorter the survival time, the two are negatively correlated ( figure 1 ), the above results suggest that PHF20 can be used as an indicator to evaluate the prognosis of patients.

Embodiment 2

[0033] Example 2: Using the breast cancer tumor auxiliary diagnosis, curative effect prediction and prognosis judgment kit provided by the present invention to detect the expression of PHF20 gene in normal breast tissue, breast cancer tissue and invasive breast cancer.

[0034] Wherein, the kits for breast cancer tumor auxiliary diagnosis, curative effect prediction and prognosis judgment include:

[0035] (1) Reagents for extracting total RNA from breast cancer tumors, including Trizol reagent, chloroform, isopropanol, and DEPC water.

[0036] (2) Reagents used for reverse transcription of total RNA into cDNA: promega reverse transcription kit (GoScriptTMReverseTranscriptase, A5003), including: GoScriptTM5X Reaction Buffer, MgCl2, PCR NucleotideMix, Recombinant Ribonuclease Inhibitor, GoScriptTMReverse Transcriptase, Nuclease-Free Water.

[0037] (3) Reagents used for real-time fluorescent quantitative PCR of cDNA, including PHF20-specific primers for real-time fluorescent qu...

Embodiment 3

[0070] Example 3: The expression of PHF20 gene in different breast cancer cell lines was detected by using the kit provided by the present invention for auxiliary diagnosis of breast cancer, prediction of curative effect and judgment of prognosis.

[0071] Detect the expression status of PHF20 in different cells, among which, breast cancer cells are MCF-7, HTB21, MDA231, HTB23, HTB25, HTB27, HTB123, MDA-MB-436, HTB123, MDA-MB-453, HTB123, MDA- MB-468; normal cells are: PBMC and MCF-10A.

[0072] The detection process is as in Example 2.

[0073] Test results: see image 3 , as can be seen from the figure, compared with normal cells, 12 breast cancer cells all show high expression of PHF20, and this expression difference can be used as a reference for judging breast cancer tumors.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a breast cancer tumor related tumor marker, an application and a kit, and relates to the technical field of tumor molecular diagnosis. The inventor, by research, finds that plant homeodomain zinc finger protein 20 (PHF20) is highly expressed in the breast cancer. And after an shRNA gene silencing method is used for down-regulating the expression level of the PHF20, the PHF20 has the obvious inhibition effect on tumor formation of breast cancer cells. The result shows that the PHF20 can be used as a drug regulation target in addition to the breast cancer marker. The invention provides a novel biomarker for breast cancer treatment and diagnosis. The PHF20 serving as the tumor marker of the breast cancer can be used for preparing the kit for breast cancer auxiliary diagnosis, curative effect prediction and prognosis judgment, and has the important clinical application value.

Description

technical field [0001] The invention relates to the technical field of tumor molecular diagnosis, in particular to a breast cancer tumor-related tumor marker and its application and kit. Background technique [0002] Breast cancer is one of the most common malignant tumors in women, and about 11% of women in the United States and other Western countries suffer from breast cancer. In my country, with the expansion of urbanization and changes in lifestyle, the number of breast cancer patients is increasing rapidly at a rate of 1.6 million per year, and 1.2 million patients die from breast cancer every year. [0003] The main reason for the death of breast cancer patients after receiving treatment is tumor drug resistance and metastasis, and cancer stem cells have the characteristics of resistance to radiotherapy and chemotherapy, so it is considered to be the root cause of tumor drug resistance and metastasis, which leads to the failure of treatment programs. Conventional rad...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886C12N15/11
CPCC12Q1/6886C12Q2600/118C12Q2600/136C12Q2600/166C12Q2600/158
Inventor 王明军赵蔚
Owner 深圳市因诺转化医学研究院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com